BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 25680186)

  • 1. 18F-FET microPET and microMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma.
    Nedergaard MK; Michaelsen SR; Urup T; Broholm H; El Ali H; Poulsen HS; Stockhausen MT; Kjaer A; Lassen U
    PLoS One; 2015; 10(2):e0115315. PubMed ID: 25680186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of (18)F-FET and (18)F-FLT small animal PET for the assessment of anti-VEGF treatment response in an orthotopic model of glioblastoma.
    Nedergaard MK; Michaelsen SR; Perryman L; Erler J; Poulsen HS; Stockhausen MT; Lassen U; Kjaer A
    Nucl Med Biol; 2016 Mar; 43(3):198-205. PubMed ID: 26924500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of longitudinal 18F-FET MicroPET imaging to evaluate response to irinotecan in orthotopic human glioblastoma multiforme xenografts.
    Nedergaard MK; Kristoffersen K; Michaelsen SR; Madsen J; Poulsen HS; Stockhausen MT; Lassen U; Kjaer A
    PLoS One; 2014; 9(2):e100009. PubMed ID: 24918622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers.
    O'Halloran PJ; Viel T; Murray DW; Wachsmuth L; Schwegmann K; Wagner S; Kopka K; Jarzabek MA; Dicker P; Hermann S; Faber C; Klasen T; Schäfers M; O'Brien D; Prehn JH; Jacobs AH; Byrne AT
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1673-83. PubMed ID: 26975402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells.
    Atzori MG; Tentori L; Ruffini F; Ceci C; Lisi L; Bonanno E; Scimeca M; Eskilsson E; Daubon T; Miletic H; Ricci Vitiani L; Pallini R; Navarra P; Bjerkvig R; D'Atri S; Lacal PM; Graziani G
    J Exp Clin Cancer Res; 2017 Aug; 36(1):106. PubMed ID: 28797294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma.
    Pöpperl G; Goldbrunner R; Gildehaus FJ; Kreth FW; Tanner P; Holtmannspötter M; Tonn JC; Tatsch K
    Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1018-25. PubMed ID: 15877226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.
    Zhang J; Xue W; Xu K; Yi L; Guo Y; Xie T; Tong H; Zhou B; Wang S; Li Q; Liu H; Chen X; Fang J; Zhang W
    Theranostics; 2020; 10(16):7245-7259. PubMed ID: 32641990
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.
    Piroth MD; Holy R; Pinkawa M; Stoffels G; Kaiser HJ; Galldiks N; Herzog H; Coenen HH; Eble MJ; Langen KJ
    Radiother Oncol; 2011 May; 99(2):218-24. PubMed ID: 21497925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.
    Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD
    J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
    Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
    World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma.
    Hayes AR; Jayamanne D; Hsiao E; Schembri GP; Bailey DL; Roach PJ; Khasraw M; Newey A; Wheeler HR; Back M
    Pract Radiat Oncol; 2018; 8(4):230-238. PubMed ID: 29730279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
    Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
    World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of Dynamic O-(2-[
    Lohmann P; Piroth MD; Sellhaus B; Weis J; Geisler S; Oros-Peusquens AM; Mohlberg H; Amunts K; Shah NJ; Galldiks N; Langen KJ
    World Neurosurg; 2018 Nov; 119():e653-e660. PubMed ID: 30077752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine.
    Galldiks N; Dunkl V; Ceccon G; Tscherpel C; Stoffels G; Law I; Henriksen OM; Muhic A; Poulsen HS; Steger J; Bauer EK; Lohmann P; Schmidt M; Shah NJ; Fink GR; Langen KJ
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2377-2386. PubMed ID: 29982845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can Early Postoperative O-(2-
    Buchmann N; Gempt J; Ryang YM; Pyka T; Kirschke JS; Meyer B; Ringel F
    World Neurosurg; 2019 Jan; 121():e467-e474. PubMed ID: 30267942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [
    Kim OS; Park JW; Lee ES; Yoo RJ; Kim WI; Lee KC; Shim JH; Chung HK
    Lab Anim Res; 2018 Dec; 34(4):248-256. PubMed ID: 30671112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [(18)F]-fluoroethyltyrosine (FET) PET/MRI: feasibility, agreement and initial experience.
    Henriksen OM; Larsen VA; Muhic A; Hansen AE; Larsson HBW; Poulsen HS; Law I
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):103-112. PubMed ID: 26363903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
    Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G
    J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TSPO Imaging in Glioblastoma Multiforme: A Direct Comparison Between 123I-CLINDE SPECT, 18F-FET PET, and Gadolinium-Enhanced MR Imaging.
    Jensen P; Feng L; Law I; Svarer C; Knudsen GM; Mikkelsen JD; de Nijs R; Larsen VA; Dyssegaard A; Thomsen G; Fischer W; Guilloteau D; Pinborg LH
    J Nucl Med; 2015 Sep; 56(9):1386-90. PubMed ID: 26182972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma.
    Lohmann P; Stavrinou P; Lipke K; Bauer EK; Ceccon G; Werner JM; Neumaier B; Fink GR; Shah NJ; Langen KJ; Galldiks N
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):591-602. PubMed ID: 30327856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.